Loss of wild type KRAS in KRAS^MUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.

ABSTRACT:

Objectives

Wild type RAS (RAS^WT) suppresses the function of oncogenic RAS mutants (RAS^MUT) in laboratory models. Loss of RAS^WT, which we termed loss of heterozygosity (LOH) for any RAS (LAR) or LAKR in the context of KRAS (LOH at KRAS), is found in patients with RAS^MUT cancers. However, the incidence and prognostic significance of LAR has not been studied in modern patient cohorts. LAR or LAKR in RAS^MUT cancers is attractive as a potential biomarker for targeted therapy.

Materials and methods

We evaluated for associations between LAKR and cancer mortality in patients with KRAS^MUT lung adenocarcinoma (LUAD). We also evaluated for associations between LAKR and the metabolic state of cancer cell lines, given that

SUBMITTER: Liu Y 

PROVIDER: S-EPMC7897317 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature